Cancer

Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were unable to have their tumours surgically removed. Researchers say that the drug combination is among the first to demonstrate the potential value of a live common cold virus, a coxsackievirus, to infect and kill […]

Kancera, a company developing a new class of drugs for the treatment of inflammation and cancer, has reported preclinical research results, which show that the company’s Fractalkine blockers have the potential to disrupt cancer cells’ resistance to chemotherapy and thereby significantly improve the treatment of advanced cancer such as ovarian cancer. The disease affects over […]

The establishment of Innovation Gateway, a high-quality incubator space for life-science companies at The London Cancer Hub in Sutton, is underway. This is a significant step in realising the aims of The London Cancer Hub, a partnership between the London Borough of Sutton and The Institute of Cancer Research, that is attempting to establish an […]

SignalChem Lifesciences, a clinical-stage company who develop novel targeted therapies for oncology, has announced its collaboration with Merck, through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC). AXL, a member of the TAM […]

The Catalogue of Somatic Mutations in Cancer (COSMIC), based at the Wellcome Sanger Institute, has launched a new feature that will allow users to see which drugs are available to target specific cancer mutations. This new resource is a positive step towards making precision oncology possible for all cancer patients. The COSMIC Mutation Actionability in […]

A team of researchers has found disrupting the interaction between cancer cells and certain immune cells is more effective at killing cancer cells than current immunotherapy treatments. The findings, which include studies in cell lines and animal models, appeared in JCI Insight and focus on a protein called CD6 as a target for a new […]

More than half of cancer patients receiving a single dose of the Pfizer COVID-19 vaccine may be left with little protection against the virus, according to a new preprint from researchers at the Francis Crick Institute and King’s College London. Data from the world’s first reported trial to examine the level of immune protection after […]

Bluebird Bio has placed its Phase I/II (HGB-206) and Phase III (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD) (bb1111) on a temporary suspension due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukaemia (AML). In line with the clinical study protocols for HGB-206 and HGB-210, the company […]

Mission Bio has launched the Tapestri Single-cell Multi-omics Solution – a comprehensive single-cell multi-omics platform. With a new instrument, single-cell multi-omics reagent kits, TotalSeq-D antibody content from BioLegend, and visualisation software, the package provides layered insight into multiple analytes across all blood cancers, reducing drug development time and cost by at least half. The company […]

Dr Michael Shepard and Sir Marc Feldmann, Enosi Life Sciences, examine the benefits of distinguishing between TNF receptors. Siloed thought processes are potentially costing the pharmaceutical industry billions of dollars per year. One particularly interesting case is that of autoimmune diseases and cancer. These two areas of medicine have a very important link – inflammation […]